GSK plc at JPMorgan Healthcare Conference Transcript
Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the GSK presentation. You're going to hear from GSK CEO, Emma Walmsley.
Thanks a lot for joining us today, Emma. I look forward to the presentation.
Thank you so much, James, and good morning. A very happy new year to you all. It is absolutely wonderful to attend today's conference and to share with everybody the progress that GSK is making. Please turn to Slide 2.
This is, of course, the usual cautionary statement, and we'll comment on our performance and forward-looking statements using constant exchange rates, or CER, unless stated otherwise. Please turn to Slide 3. GSK is a global biopharma company focused on the prevention and the treatment of disease with clear performance momentum as we head into 2024.
In the first 9 months of 2023, we delivered double-digit sales and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |